Introduction And Pathophysiological Rationale
- High-Frequency Oscillatory Ventilation (HFOV) is a lung-protective ventilation strategy that delivers extremely small tidal volumes (1 to 3 mL/kg) at highly elevated frequencies (3 to 15 Hz) utilizing active exhalation.
- It achieves effective gas exchange through bulk flow, pendelluft, and asymmetric velocity profiles while employing sub-dead-space tidal volumes.
- This modality minimizes ventilator-induced lung injury (VILI), volutrauma, and atelectrauma while sustaining a constant mean airway pressure (MAP) to ensure optimal alveolar recruitment.
- In India, pediatric acute respiratory distress syndrome (PARDS) and neonatal acute respiratory distress syndrome (NARDS) carry substantial morbidity, making HFOV a critical rescue option where extracorporeal membrane oxygenation (ECMO) remains unavailable.
Latest Research And Clinical Evidence (2025-2026)
- A 2026 randomized controlled trial (RCT) demonstrated that elective HFOV significantly reduces bronchopulmonary dysplasia (BPD) incidence (34.3% versus 44.9%) and lowers the risk of severe BPD by 32% in preterm infants.
- A 2025 RCT established that non-invasive HFOV (NHFOV) utilized as primary respiratory support significantly diminishes the requirement for invasive mechanical ventilation within 72 hours compared to nasal CPAP in extremely preterm neonates.
- Volume-guarantee HFOV (HFOV-VG) demonstrates emerging clinical feasibility for controlling tidal volumes, successfully mitigating amplitude variability in neonates.
- The ongoing PROSpect trial protocol evaluates the efficacy of HFOV combined with prone positioning versus conventional mechanical ventilation (CMV) in moderate-to-severe PARDS.
- Real-world cohorts from resource-limited settings confirm that HFOV improves oxygenation as a rescue therapy, though it provides no routine mortality benefit over CMV.
Current Society Guidelines And Recommendations
| Governing Society | Specific Clinical Recommendations |
|---|---|
| PALICC-2 (2023, 2025 Reviews) | Does not recommend routine HFOV use over CMV in PARDS; reserves HFOV strictly as rescue therapy when lung-protective CMV fails (plateau pressure >28 cmH2O). |
| Surviving Sepsis Campaign (SSC) 2026 | Suggests conditional use of HFOV as a rescue strategy for refractory hypoxemia in sepsis and PARDS, with no routine preference over CMV. |
| ESPNIC And UK Guidelines (2025) | Supports the elective use of HFOV in preterm NARDS specifically for BPD prevention and recommends NHFOV as primary support in extremely preterm infants. |
| IAP Critical Care Modules (2025-2026) | Aligns with PALICC-2 algorithms, recommending HFOV exclusively as rescue therapy in Indian PICUs when CMV proves inadequate. |
Clinical Implementation And Titration Protocols
- For neonates, clinicians must initiate HFOV at frequencies of 10 to 15 Hz with a MAP set 2 to 5 cmH2O above previous CMV settings.
- For older children, the recommended frequency is 5 to 10 Hz requiring relatively higher MAP titrations.
- Optimization of lung volume requires a stepwise MAP increase or decrease while meticulously monitoring oxygenation, carbon dioxide response, and systemic hemodynamics.
- The MoHFW and ICMR Standard Treatment Workflows have officially incorporated HFOV as a rescue ventilation modality in severe PARDS and NARDS PICU protocols.
- Implementation challenges include substantial operator dependence, significant heterogeneity in clinical trials, and limited availability of specialized equipment in resource-limited settings.